Mechanistically, this antifibrotic effect is mediated through suppression of the TGF-β1/Smad signaling axis, highlighting its therapeutic potential to disrupt profibrotic pathways central to SSc pathogenesis (Brown Lobbins et al. 2021). Here, TGFB1 is linked to systemic sclerosis.